XPOVIO®
(selinexor)

XPOVIO is the first and only FDA-approved oral XPO1 inhibitor that gets to the cell's nucleus, which leads to cell cycle arrest and apoptosis in cancer cells[1]

XPOVIO Mechanism of Action



*Cargos include tumor suppressor proteins (p53, p73, FOXO3a, IκB, pRb, BRCA1), growth regulators (glucocorticoid receptors), and oncoprotein mRNA (c-Myc, cyclin D, Bcl-2, Bcl-6).[3,4,6,8,9] The identified cargos do not represent all cargos exported by XPO1.

For illustrative purposes only.

INDICATION

- XPOVIO® (selinexor) is a prescription medicine approved in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma who have received at least one prior therapy.

SELECTED SAFETY INFORMATION

- The most common ARs (≥20%) were fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting.
- Grade 3-4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia.
- The treatment discontinuation rate due to ARs was 19%; 64% of patients had a reduction in the XPOVIO dose, and 83% had the dose of XPOVIO interrupted.

Please see full Prescribing Information at XPOVIOpro.com.

To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1-888-209-9326 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References: 1. XPOVIO (selinexor) [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; December 2020. **2.** Yang J, Bill MA, Young GS, et al. *PLoS One*. 2014;9(7):e102983. **3.** Gupta A, Saltarski JM, White MA, Scaglioni PP, Gerber DE. *J Thorac Oncol.* 2017;12(9):1446-1450. **4.** Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Jia D. *Signal Transduct Target Ther.* 2016;1:16010. **5.** Mor A, White MA, Fontoura BM. *Curr Opin Cell Biol.* 2014;28:28-35. **6.** Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. *J Hematol Oncol.* 2014;7:85. **7.** Tai YT, Landesman Y, Acharya C, et al. *Leukemia.* 2014;28(1):155-165. **8.** Ben-Barouch S, Kuruvilla J. *Expert Opin Investig Drugs.* 2020;29(1):15-21. **9.** Gandhi UH, Senapedis W, Baloglu E, et al. *Clin Lymphoma Myeloma Leuk.* 2018;18(5):335-345.

Karyopharm® Therapeutics